All News

Jeffrey Sparks MD MMSc Tweet
jeffsparks
Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor. 46% flared Seropositive- OR 2.0 NO association with mortality -ICIs are safe to use in RA -Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
Dr. Antoni Chan Tweet
LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I
Janet Pope Tweet
Rx of #inflammatory #arthritis with #glucocorticoids doesn’t seem to affect outcomes in #malignancy treated with #checkpoint #inhibitors. Good news as new or flaring inflammatory arthritis as an irAE can be severe. #ACR23 @RheumNow @ACRheum #1055 @CanRIO_Tweets https://t.co/tFIPcQq2X6
Aurelie Najm Tweet
Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
sheila Tweet
The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis. Intervention included food delivery svc & probiotic shot Limitations included study design issues such small sample size #ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
Dr. Antoni Chan Tweet
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP
Aurelie Najm Tweet
Synovial tissue histology correlates w/ several clinical parameters in early naive RA Combination ohigh CD68 infiltrate Fibrinoid Necrosis in tissue asso w/ -better DA reduction -higher EULAR moderate/good resp Included in a prediction model (AUC0.7) @RheumNow #ACR23 ABST2483 https://t.co/2jCMSzV7ak
Aurelie Najm Tweet
Body mass is associated w/ ttmt response in RA Data from RACAT & TEAR studies TNFi > triple th in underweight gpe but not in overweight gpe Similar result in gpe w/ low leptin levels & low adipokine scores True biology or confounding bias? @RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa
Janet Pope Tweet
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
David Liew Tweet
drdavidliew
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly. Gene expression signatures might tell us more - one key cluster here was 21x predictive. #ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
Bella Mehta Tweet
bella_mehta
Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0
Aurelie Najm Tweet
Gene signature predicts RA trajectory during pregnancy: Blood RNAseq *before* pregnancy 🚺 improve during preg: Strong Neutrophil signature 🚺 experience dis worsening: Strong B cell signature Needs replication but could have major implications! @RheumNow #ACR23 ABST2481 https://t.co/gOHwEvOOM6
Aurelie Najm Tweet
Anti-fibrotics in RA-ILD Retro analysis of 74 pts AEs frequent 55% and discontinuation in 46% (more than in initial RCTs) No diff between AF FCV trajectory mildly improved ABST2479 @RheumNow @Juge_P_A @PhilippeDieude #ACR23 https://t.co/GqsHxkIFgD
Eric Dein Tweet
GCs on MACE in RA in VA A#2430 #ACR23 @RheumNow Not just ongoing steroid usage, also prior usage 1 year ago 5 mg use for 30 days one year ago - increases MACE events by 3% 5 mg use for 90 days one year ago - increases MACE events by 9%
Richard Conway Tweet
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o
Robert B Chao, MD Tweet
Even low doses of steroids associated with major adverse cardiovascular events! Large VA database - >18k RA pts Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE @RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD
×